RealFeedApp Manufacturing execution blocks scientific innovation in biopharma
Nicolas Pivet from Cytiva states that the industry's primary hurdle is manufacturing execution rather than scientific innovation. Existing production environments were developed over decades without intentional design for modern scalability.
- Field
- industry news
- What they did
- Nicolas Pivet, vice president and general manager of manufacturing and digital solutions at Cytiva, states that the biggest challenge facing the biopharma industry is not scientific innovation, but manufacturing execution.
- Why it matters
- Although major scientific advances have enabled the development of amazing therapeutics such as RNA technologies and cell and gene interventions, manufacturing innovation hasn't kept pace, making reliable and scalable production a major constraint.
#biopharma#manufacturing#nicolas pivet#cytiva#execution
